Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Whole-Genome Testing Could Become Diagnosis Tool

Case Studies of Cancer Patients Reveal Medical Potential of Quick Sequencing of Genomes
By
WebMD Health News
Reviewed by Laura J. Martin, MD

April 19, 2011 -- Less than a decade after the first human genome was sequenced at a cost of hundreds of millions of dollars, whole-genome sequencing is poised to become a useful and affordable diagnostic tool, experts say.

Technological advances allow researchers to sequence entire genomes at a speed and cost that was unimaginable just a few years ago.

Now two new case studies appearing this week in TheJournal of the American Medical Association show the value of whole-genome sequencing in the management of certain cancers.

“My expectation is that within just a few years whole-genome sequencing will be no more expensive than targeted sequencing and it will tell us much more,” cancer genetics researcher Boris Pasche, MD, PhD, of the University of Alabama at Birmingham tells WebMD.

How Whole-Genome Sequencing Works

Testing for specific mutations, such as BRCA1 and BRCA2 in breast cancer and ovarian cancer, is now commonly performed when the mutations are suspected.

But these tests focus on genes, which make up a very small percentage of the genome. Whole-genome sequencing searches for all genetic alterations in DNA that can affect susceptibility to cancer and other diseases.

Washington University oncology professor Timothy Ley, MD, calls whole-genome sequencing the most powerful diagnostic tool ever for understanding specific mutations that influence cancer susceptibility.

“We are in the very early stages of understanding what to do with the data provided by whole-genome sequencing,” he tells WebMD. “The more genomes we sequence, the more we will understand about how mutations influence outcomes.”

He says the two cases reported in The Journal of the American Medical Association highlight the potential value of whole-genome sequencing for providing meaningful information.

Testing Reveals Unsuspected Mutations

One case involved a woman who developed breast cancer at age 37, followed by ovarian cancer at age 39. Despite treatment, the ovarian cancer returned. The woman died at the age of 42, just days after being diagnosed with acute myeloid leukemia.

The woman had little family history of cancer, and testing for known susceptibility genes, such as BRCA1 and BRCA2, proved negative.

Genomic testing identified an unexpected mutation in the tumor suppressor gene TP53, which caused a rare disorder known as Li-Fraumeni syndrome.

“The syndrome carries a 90% lifetime risk of developing breast cancer and a 50% chance of developing cancer before the age of 40,” Pasche says. “It is a ticking time bomb.”

The discovery did not help the patient, but it could have major implications for her three young children, who have a 50% chance of inheriting the genetic error.

“We now know that aggressive screening and a variety of interventions, such as prophylactic mastectomy, can have a real impact on outcomes,” Pasche says.

Testing Helps Identify Treatment

The second case involved a young woman with acute myeloid leukemia.

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article